Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
Public ClinicalTrials.gov record NCT00897663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Optimizing EGFR Inhibitor-Based Therapies for GBM
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at tissue samples from patients with glioblastoma multiforme to identify biomarkers that may improve the selection of patients for epidermal growth factor receptor inhibitor therapies.
Study identification
- NCT ID
- NCT00897663
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- gene expression analysis Genetic
- microarray analysis Genetic
- protein expression analysis Genetic
- diagnostic laboratory biomarker analysis Other
- immunohistochemistry staining method Other
Genetic · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Dec 31, 2017
- Completion
- Dec 31, 2017
- Last update posted
- Jan 23, 2018
2006 – 2018
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Scottsdale | Scottsdale | Arizona | 85259-5499 | — |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| Siouxland Hematology-Oncology Associates, LLP | Sioux City | Iowa | 51101 | — |
| Mercy Medical Center - Sioux City | Sioux City | Iowa | 51102 | — |
| St. Luke's Regional Medical Center | Sioux City | Iowa | 51104 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| Medcenter One Hospital Cancer Care Center | Bismarck | North Dakota | 58501 | — |
| Mid Dakota Clinic, PC | Bismarck | North Dakota | 58501 | — |
| St. Alexius Medical Center Cancer Center | Bismarck | North Dakota | 58502 | — |
| Rapid City Regional Hospital | Rapid City | South Dakota | 57701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00897663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 23, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00897663 live on ClinicalTrials.gov.